|Company name||Ligand Pharmaceuticals Incorporated|
NEW YORK, January 29, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against Ligand Pharmaceuticals Incorporated (NYSE: LGND). Our investigation concerns whether Ligand has violated the federal securities laws and/or engaged in other unlawful business practices.
On January 16, 2019, Citron Research published a report entitled “Pipeline Ligand Pipe Dream,” describing its observations of Ligand’s business. The report detailed sources of future revenues by drug candidate, showing that roughly 60% of Ligand’s milestone payments stem from just two companies. The report goes on to allege that some of Ligand’s partners have corporate addresses that are actually a private residence or UPS box, or do not occupy their supposed address.
On this news, Ligand’s share price fell by more than 16%, closing at $110.05 on January 16, 2019.
If you purchased or otherwise acquired Ligand shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.